SUBA itraconazole

Phase 2Small molecule

HHalcygen Pharmaceuticals Limited

SUBA itraconazole is one of 93 small molecule programs targeting Coccidioidomycosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CoccidioidomycosisActive, not recruiting

Basal Cell CarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

CoccidioidomycosisPhase 2

Active, not recruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

SUBA itraconazole

HHalcygen Pharmaceuticals Limited

Phase 2

1 2

Novantrone

Pfizer

Preclinical

5 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

9 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Ovarian Cancer

NCT05156892

Clinical

Trials by Indication[1]

Treatment1 trial

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT03572049·88 enrolled

Coccidioidomycosis1 trial

SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole

Withdrawn·GGeorge R Thompson·Phase 2·NCT04809649

Prostate Cancer1 trial

Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

Completed·SSt Vincent's Hospital, Sydney·Phase 1/2·NCT03513211·12 enrolled

Ovarian Cancer1 trial

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Active, not recruiting·AAnthony Joshua, FRACP·Phase 1·NCT05156892·44 enrolled

Onychomycosis1 trial

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

Completed·HHalcygen Pharmaceuticals Limited·Phase 2·NCT00791219·175 enrolled

1 more indication

Basal Cell Carcinoma1 trial

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Completed·HHedgePath Pharmaceuticals, Inc.·Phase 2·NCT02354261·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for SUBA itraconazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SUBA itraconazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SUBA itraconazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Halcygen Pharmaceuticals Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHalcygen Pharmaceuticals Limited

SUBA itraconazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Treatment1 trial

Coccidioidomycosis1 trial

Prostate Cancer1 trial

Ovarian Cancer1 trial

Onychomycosis1 trial

Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News